Suresh Ramalingam

Suresh Ramalingam is a globally recognized leader in lung cancer therapeutics, serving as executive director of Winship Cancer Institute at Emory University. He led pivotal ADAURA and FLAURA trials establishing osimertinib as the standard of care for EGFR-mutant NSCLC in the adjuvant and first-line settings. His research has fundamentally altered outcomes for hundreds of thousands of patients with EGFR-driven lung cancer. He serves on the boards of major oncology organizations and has received numerous awards for translational cancer research.